Combined effects on tumor growth and metastasis by anti-estrogenic and antiangiogenic therapies in MMTV-neu mice.
Breast tumor growth and metastasization are both hormone-sensitive and angiogenesis-dependent. Recent work carried out in our laboratory on a transgenic model of breast cancer displaying many similarities to its human counterpart, has shown that liposome-mediated angiostatin cDNA delivery partially inhibits both local and metastatic growth. However, it is now recognized that anti-angiogenesis strategy alone cannot completely arrest tumor growth and spread, and this led to the suggestion that approaches based on different molecular mechanisms could usefully be combined. In the present work, we investigated whether tamoxifen, a classical antiestrogen agent widely used in human therapy, could improve the results obtained with angiostatin alone. Further reduction of local growth was achieved with the combined regimen with respect to angiostatin or tamoxifen alone, while, as expected, no metastatic growth was detected in either group. We therefore conclude that a combination of angiogenesis inhibitors with antiestrogen drugs might be useful in humans and that other associations between conventional and gene transfer-mediated therapy are worth investigating and will soon become important components of anticancer therapy.
Sacco
M G
MG
Department of Human Genome and Multifactorial Diseases, Istituto di Tecnologie Biomediche, ITB-CNR, Milan, Italy.
Soldati
S
S
Mira Cató
E
E
Cattaneo
L
L
Pratesi
G
G
Scanziani
E
E
Vezzoni
P
P
D020533:Angiogenesis Inhibitors / Q000235:genetics / Q000378:metabolism; D043168:Angiostatins; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018076:DNA, Complementary / Q000235:genetics; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy / Q000628:therapy*; D051379:Mice; D008822:Mice, Transgenic; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D010446:Peptide Fragments / Q000235:genetics* / Q000378:metabolism; D010958:Plasminogen / Q000235:genetics* / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D018931:Antineoplastic Agents, Hormonal; D018076:DNA, Complementary; D010446:Peptide Fragments; D013629:Tamoxifen; D043168:Angiostatins; D010958:Plasminogen